How are MRNA strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MRNA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 75.15%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$629.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a MRNA strangle?

The breakeven for the MRNA strangle priced on this page is roughly $39.71 and $57.30 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MRNA market-implied 1-standard-deviation expected move is approximately 21.55%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current MRNA implied volatility affect this strangle?

MRNA ATM IV is at 75.15% with IV rank near 60.16%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

MRNA Strangle Strategy

MRNA (Moderna, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

MRNA (Moderna, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $20.01B, a beta of 1.06 versus the broader market, a 52-week range of 22.28-59.55, average daily share volume of 8.1M, a public-listing history dating back to 2018, approximately 6K full-time employees. These structural characteristics shape how MRNA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.06 places MRNA roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on MRNA?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current MRNA snapshot

As of May 15, 2026, spot at $48.89, ATM IV 75.15%, IV rank 60.16%, expected move 21.55%. The strangle on MRNA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this strangle structure on MRNA specifically: MRNA IV at 75.15% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 21.55% (roughly $10.53 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MRNA expiries trade a higher absolute premium for lower per-day decay. Position sizing on MRNA should anchor to the underlying notional of $48.89 per share and to the trader's directional view on MRNA stock.

MRNA strangle setup

The MRNA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MRNA near $48.89, the first option leg uses a $51.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MRNA chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MRNA shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$51.00	$3.35
Buy 1	Put	$46.00	$2.95

MRNA strangle risk and reward

Net Premium / Debit: -$629.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$629.50
Breakeven(s): $39.71, $57.30
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

MRNA strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on MRNA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$3,969.50
$10.82	-77.9%	+$2,888.63
$21.63	-55.8%	+$1,807.75
$32.44	-33.7%	+$726.88
$43.24	-11.5%	-$354.00
$54.05	+10.6%	-$324.13
$64.86	+32.7%	+$756.75
$75.67	+54.8%	+$1,837.62
$86.48	+76.9%	+$2,918.49
$97.29	+99.0%	+$3,999.37

When traders use strangle on MRNA

Strangles on MRNA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MRNA chain.

MRNA thesis for this strangle

The market-implied 1-standard-deviation range for MRNA extends from approximately $38.36 on the downside to $59.42 on the upside. A MRNA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current MRNA IV rank near 60.16% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on MRNA should anchor more to the directional view and the expected-move geometry. As a Healthcare name, MRNA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MRNA-specific events.

MRNA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MRNA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MRNA alongside the broader basket even when MRNA-specific fundamentals are unchanged. Always rebuild the position from current MRNA chain quotes before placing a trade.

Frequently asked questions

What is a strangle on MRNA?: A strangle on MRNA is the strangle strategy applied to MRNA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With MRNA stock trading near $48.89, the strikes shown on this page are snapped to the nearest listed MRNA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are MRNA strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MRNA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 75.15%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$629.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a MRNA strangle?: The breakeven for the MRNA strangle priced on this page is roughly $39.71 and $57.30 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MRNA market-implied 1-standard-deviation expected move is approximately 21.55%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on MRNA?: Strangles on MRNA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MRNA chain.
How does current MRNA implied volatility affect this strangle?: MRNA ATM IV is at 75.15% with IV rank near 60.16%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.